Lupus is an autoimmune rheumatic condition that causes the immune system to start working against different parts of the body, including joints and organ systems. It tends to cause increased inflammation in the body.
It’s an intriguing and challenging condition because of how it varies—not only from person to person, but also day to day.
Medicine is typically pretty black or white, but when it comes to autoimmune diseases like lupus, there’s a gray zone of relative uncertainty. Lupus can present on a spectrum, and can manifest in a number of different ways, occasionally mimicking other conditions.
It can be unpredictable, and the majority of sufferers still aren’t equipped with adequate knowledge of the condition and some of its ramifications.
Few AIM-listed drug development companies have late-stage clinical assets in the pipeline, ImmuPharma plc (LON:IMM) is an exception. The Company’s lead compound, Lupuzor™, a potential treatment for Lupus, has completed Phase 3 trial of dosing patients across the US, Europe and Mauritius with top line results announced.
